IN2012DN03337A - - Google Patents
Info
- Publication number
- IN2012DN03337A IN2012DN03337A IN3337DEN2012A IN2012DN03337A IN 2012DN03337 A IN2012DN03337 A IN 2012DN03337A IN 3337DEN2012 A IN3337DEN2012 A IN 3337DEN2012A IN 2012DN03337 A IN2012DN03337 A IN 2012DN03337A
- Authority
- IN
- India
- Prior art keywords
- compounds
- formula
- well
- pharmaceutically acceptable
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09173178 | 2009-10-15 | ||
PCT/EP2010/065232 WO2011045292A1 (en) | 2009-10-15 | 2010-10-12 | Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03337A true IN2012DN03337A (el) | 2015-10-23 |
Family
ID=43093680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3337DEN2012 IN2012DN03337A (el) | 2009-10-15 | 2010-10-12 |
Country Status (20)
Country | Link |
---|---|
US (1) | US8440710B2 (el) |
EP (1) | EP2488493B1 (el) |
JP (1) | JP5749272B2 (el) |
KR (1) | KR101576328B1 (el) |
CN (1) | CN102858743B (el) |
AR (1) | AR078619A1 (el) |
AU (1) | AU2010305859A1 (el) |
BR (1) | BR112012008962A2 (el) |
CA (1) | CA2776457A1 (el) |
CL (1) | CL2012000937A1 (el) |
ES (1) | ES2538005T3 (el) |
IL (1) | IL218958A0 (el) |
IN (1) | IN2012DN03337A (el) |
MX (1) | MX2012004311A (el) |
PE (1) | PE20121732A1 (el) |
PH (1) | PH12012500630A1 (el) |
RU (1) | RU2607080C2 (el) |
TW (1) | TW201118068A (el) |
WO (1) | WO2011045292A1 (el) |
ZA (1) | ZA201202613B (el) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102361874A (zh) | 2009-03-23 | 2012-02-22 | 格兰马克药品股份有限公司 | 作为trpa1调节剂的呋喃并嘧啶二酮衍生物 |
US8097634B2 (en) * | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
US8722721B2 (en) | 2011-03-16 | 2014-05-13 | Hoffmann-La Roche Inc. | SEC-hydroxycyclohexyl derivatives |
US8703807B2 (en) * | 2011-03-17 | 2014-04-22 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
US8809384B2 (en) * | 2011-03-25 | 2014-08-19 | Hoffmann-La Roche Inc. | Azaspirodecanone compounds |
CN103319395B (zh) * | 2013-04-08 | 2014-09-24 | 武汉罗化科技有限公司 | 一种4-氟靛红的工业化制备方法及其产品 |
WO2015103756A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
MX2020004405A (es) | 2017-11-01 | 2020-08-06 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x. |
WO2019089665A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid x receptor modulators |
ES2944657T3 (es) | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos de alqueno como moduladores del receptor farnesoide X |
EP3704107B1 (en) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
EA202091101A1 (ru) | 2017-11-01 | 2020-08-06 | Бристол-Маерс Сквибб Компани | Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора |
CN109369354B (zh) * | 2018-12-15 | 2021-07-09 | 浦拉司科技(上海)有限责任公司 | 一种4,4,4-三氟丁醇的合成方法 |
CA3129619A1 (en) | 2019-02-15 | 2020-08-20 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
US12319676B2 (en) | 2019-02-15 | 2025-06-03 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid X receptor modulators |
BR112021015930A2 (pt) | 2019-02-15 | 2021-10-05 | Bristol-Myers Squibb Company | Compostos de amida substituídos úteis como moduladores de receptor farnesoide x |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10247680B4 (de) | 2002-10-12 | 2005-09-01 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
BRPI0417663A (pt) | 2003-12-16 | 2007-04-03 | Pfizer Prod Inc | pirido[2,3-d]pirimidina-2,4diaminas como inibidores de pde 2 |
FR2870538B1 (fr) * | 2004-05-19 | 2006-07-14 | Servier Lab | Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
DE602007007211D1 (de) * | 2006-04-25 | 2010-07-29 | Lilly Co Eli | Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1 |
EP2021337B1 (en) * | 2006-04-25 | 2010-01-13 | Eli Lilly And Company | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
GB0705656D0 (en) | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
-
2010
- 2010-10-08 US US12/900,621 patent/US8440710B2/en not_active Expired - Fee Related
- 2010-10-12 EP EP10770764.8A patent/EP2488493B1/en not_active Not-in-force
- 2010-10-12 MX MX2012004311A patent/MX2012004311A/es active IP Right Grant
- 2010-10-12 CA CA2776457A patent/CA2776457A1/en not_active Abandoned
- 2010-10-12 AU AU2010305859A patent/AU2010305859A1/en not_active Abandoned
- 2010-10-12 JP JP2012533604A patent/JP5749272B2/ja not_active Expired - Fee Related
- 2010-10-12 IN IN3337DEN2012 patent/IN2012DN03337A/en unknown
- 2010-10-12 KR KR1020127012343A patent/KR101576328B1/ko not_active Expired - Fee Related
- 2010-10-12 RU RU2012119706A patent/RU2607080C2/ru not_active IP Right Cessation
- 2010-10-12 PH PH1/2012/500630A patent/PH12012500630A1/en unknown
- 2010-10-12 BR BR112012008962A patent/BR112012008962A2/pt not_active IP Right Cessation
- 2010-10-12 WO PCT/EP2010/065232 patent/WO2011045292A1/en active Application Filing
- 2010-10-12 ES ES10770764.8T patent/ES2538005T3/es active Active
- 2010-10-12 CN CN201080046313.0A patent/CN102858743B/zh not_active Expired - Fee Related
- 2010-10-12 TW TW099134747A patent/TW201118068A/zh unknown
- 2010-10-12 PE PE2012000489A patent/PE20121732A1/es not_active Application Discontinuation
- 2010-10-13 AR ARP100103732A patent/AR078619A1/es unknown
-
2012
- 2012-03-29 IL IL218958A patent/IL218958A0/en unknown
- 2012-04-11 ZA ZA2012/02613A patent/ZA201202613B/en unknown
- 2012-04-13 CL CL2012000937A patent/CL2012000937A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR101576328B1 (ko) | 2015-12-10 |
CN102858743B (zh) | 2015-06-10 |
CA2776457A1 (en) | 2011-04-21 |
AR078619A1 (es) | 2011-11-23 |
HK1179957A1 (en) | 2013-10-11 |
JP5749272B2 (ja) | 2015-07-15 |
US8440710B2 (en) | 2013-05-14 |
WO2011045292A1 (en) | 2011-04-21 |
PH12012500630A1 (en) | 2012-10-22 |
PE20121732A1 (es) | 2012-12-28 |
KR20120074304A (ko) | 2012-07-05 |
EP2488493B1 (en) | 2015-04-15 |
US20110092512A1 (en) | 2011-04-21 |
EP2488493A1 (en) | 2012-08-22 |
MX2012004311A (es) | 2012-04-30 |
RU2012119706A (ru) | 2013-11-20 |
JP2013507421A (ja) | 2013-03-04 |
TW201118068A (en) | 2011-06-01 |
CN102858743A (zh) | 2013-01-02 |
ES2538005T3 (es) | 2015-06-16 |
IL218958A0 (en) | 2012-06-28 |
RU2607080C2 (ru) | 2017-01-10 |
AU2010305859A1 (en) | 2012-06-07 |
CL2012000937A1 (es) | 2012-09-14 |
ZA201202613B (en) | 2013-01-30 |
BR112012008962A2 (pt) | 2019-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03337A (el) | ||
MX2010005824A (es) | Derivados de aminotiazol. | |
TW200738241A (en) | Pyridazine derivatives | |
MY138941A (en) | Aryl-pyridine derivatives | |
MX2011012017A (es) | Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl). | |
SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
UA102310C2 (ru) | Гетероциклические сульфонамиды, их применение и фармацевтические композиции | |
MX2012000414A (es) | Derivados piridin-4-ilo. | |
IN2012DN01232A (el) | ||
MX2009003939A (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. | |
TW200740764A (en) | Pyrazolone derivatives | |
IN2012DN01233A (el) | ||
MY153921A (en) | Aminopyrazole derivatives | |
PH12013500942A1 (en) | Triazolopyridine compounds | |
DE602006021539D1 (en) | Morpholine als 5ht2c-agonisten | |
MX2012007536A (es) | Derivados de heteroarilo que contienen nitrogeno. | |
MX2010005714A (es) | Compuestos de piridina. | |
MX2008016426A (es) | Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1). | |
MX2009010567A (es) | Derivados de imidazolidinona. | |
IN2012DN00765A (el) | ||
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
MX2011008360A (es) | Derivados de piridazinona sustituida con heteroarilo. | |
MY183039A (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
TW200616976A (en) | Pyrimidine derivatives | |
MX2009003169A (es) | Derivados de sulfonamida. |